Verma, S.; Breadner, D.; Mittal, A.; Palma, D.A.; Nayak, R.; Raphael, J.; Vincent, M.
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers 2024, 16, 1302.
https://doi.org/10.3390/cancers16071302
AMA Style
Verma S, Breadner D, Mittal A, Palma DA, Nayak R, Raphael J, Vincent M.
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers. 2024; 16(7):1302.
https://doi.org/10.3390/cancers16071302
Chicago/Turabian Style
Verma, Saurav, Daniel Breadner, Abhenil Mittal, David A. Palma, Rahul Nayak, Jacques Raphael, and Mark Vincent.
2024. "An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy" Cancers 16, no. 7: 1302.
https://doi.org/10.3390/cancers16071302
APA Style
Verma, S., Breadner, D., Mittal, A., Palma, D. A., Nayak, R., Raphael, J., & Vincent, M.
(2024). An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers, 16(7), 1302.
https://doi.org/10.3390/cancers16071302
